S100A10 and chronic myelogenous leukemia, BCR-ABL1 positive: Of the significant genotypic category, GP13 and GP11 conferred approximately 10 and 8-fold higher risk of CML development, respectively, while GP14 was associated with a strong protective effect reducing CML susceptibility about four-fold (Figure 1b).